Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Summary of Revenue by Sales Category

The following tables provide detail by sales category:

	2022						2021						2020
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	3,728	$	3,728	$	—	$	3,539	$	3,539	$	—	$	3,209	$	3,209
Other	—		1,184		1,184		—		1,179		1,179		—		1,094		1,094
Total	—		4,912		4,912		—		4,718		4,718		—		4,303		4,303
Nutritionals —
Pediatric Nutritionals	1,562		1,919		3,481		2,192		2,106		4,298		1,987		2,140		4,127
Adult Nutritionals	1,357		2,621		3,978		1,364		2,632		3,996		1,292		2,228		3,520
Total	2,919		4,540		7,459		3,556		4,738		8,294		3,279		4,368		7,647
Diagnostics —
Core Laboratory	1,137		3,751		4,888		1,145		3,983		5,128		1,166		3,309		4,475
Molecular	370		625		995		566		861		1,427		621		817		1,438
Point of Care	372		153		525		384		152		536		369		147		516
Rapid Diagnostics	6,767		3,409		10,176		5,034		3,519		8,553		2,618		1,758		4,376
Total	8,646		7,938		16,584		7,129		8,515		15,644		4,774		6,031		10,805
Medical Devices —
Rhythm Management	1,029		1,090		2,119		1,018		1,180		2,198		903		1,011		1,914
Electrophysiology	909		1,018		1,927		778		1,129		1,907		660		918		1,578
Heart Failure	694		226		920		654		235		889		547		193		740
Vascular	864		1,619		2,483		915		1,739		2,654		853		1,486		2,339
Structural Heart	818		894		1,712		730		880		1,610		540		707		1,247
Neuromodulation	619		151		770		616		165		781		564		138		702
Diabetes Care	1,633		3,123		4,756		1,212		3,116		4,328		864		2,403		3,267
Total	6,566		8,121		14,687		5,923		8,444		14,367		4,931		6,856		11,787
Other	11		—		11		34		18		52		38		28		66
Total	$	18,142	$	25,511	$	43,653	$	16,642	$	26,433	$	43,075	$	13,022	$	21,586	$	34,608

Schedule of Changes in Contract Liabilities

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2020	$	405
Unearned revenue from cash received during the period	615
Revenue recognized related to contract liability balance	(500)
Balance at December 31, 2021	520
Unearned revenue from cash received during the period	578
Revenue recognized related to contract liability balance	(598)
Balance at December 31, 2022	$	500